146 related articles for article (PubMed ID: 30449848)
1. [Pemetrexed for Treatment of Nonsquamous Non-Small-Cell Lung Cancer].
Omori Y; Enatsu S
Gan To Kagaku Ryoho; 2018 Nov; 45(11):1609-1613. PubMed ID: 30449848
[TBL] [Abstract][Full Text] [Related]
2. Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non-Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care.
Patel JD; Paz-Ares L; Zinner RG; Barlesi F; Koustenis AG; Obasaju CK
Clin Lung Cancer; 2018 Nov; 19(6):e823-e830. PubMed ID: 30369427
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.
Zeng X; Peng L; Li J; Chen G; Tan C; Wang S; Wan X; Ouyang L; Zhao Z
Clin Ther; 2013 Jan; 35(1):54-65. PubMed ID: 23328269
[TBL] [Abstract][Full Text] [Related]
4. Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label randomized phase II study.
Kubota K; Niho S; Enatsu S; Nambu Y; Nishiwaki Y; Saijo N; Fukuoka M
J Thorac Oncol; 2009 Dec; 4(12):1530-6. PubMed ID: 19755925
[TBL] [Abstract][Full Text] [Related]
5. Rationale and Design of PEMVITASTART-An Open-label Randomized Trial Comparing Simultaneous Versus Standard Initiation of Vitamin B
Baldi M; Behera D; Kaur J; Kapoor R; Singh N
Clin Lung Cancer; 2017 Jul; 18(4):432-435. PubMed ID: 28073680
[TBL] [Abstract][Full Text] [Related]
6. Pemetrexed With Platinum Combination as a Backbone for Targeted Therapy in Non-Small-Cell Lung Cancer.
Stinchcombe TE; Borghaei H; Barker SS; Treat JA; Obasaju C
Clin Lung Cancer; 2016 Jan; 17(1):1-9. PubMed ID: 26340853
[TBL] [Abstract][Full Text] [Related]
7. Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer.
Liang Y; Wakelee HA; Neal JW
Clin Lung Cancer; 2015 Sep; 16(5):366-73. PubMed ID: 25665893
[TBL] [Abstract][Full Text] [Related]
8. Molecular Factors Associated with Pemetrexed Sensitivity According to Histological Type in Non-small Cell Lung Cancer.
Yoshida T; Okamoto T; Yano T; Takada K; Kohno M; Suda K; Takenoyama M; Oda Y; Maehara Y
Anticancer Res; 2016 Dec; 36(12):6319-6326. PubMed ID: 27919952
[TBL] [Abstract][Full Text] [Related]
9. Estimated Creatinine Clearance Rate Is Associated With the Treatment Effectiveness and Toxicity of Pemetrexed As Continuation Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Chen CY; Lin JW; Huang JW; Chen KY; Shih JY; Yu CJ; Yang PC
Clin Lung Cancer; 2015 Nov; 16(6):e131-40. PubMed ID: 25659505
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials.
Scagliotti GV; Gridelli C; de Marinis F; Thomas M; Dediu M; Pujol JL; Manegold C; San Antonio B; Peterson PM; John W; Chouaki N; Visseren-Grul C; Paz-Ares LG
Lung Cancer; 2014 Sep; 85(3):408-14. PubMed ID: 25088661
[TBL] [Abstract][Full Text] [Related]
11. Pemetrexed for the treatment of non-small-cell lung cancer.
Manegold C; Schmid-Bindert G; Pilz LR
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1195-209. PubMed ID: 19761423
[TBL] [Abstract][Full Text] [Related]
12. The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy.
Molina JR; Adjei AA
Clin Lung Cancer; 2003 Jul; 5(1):21-7. PubMed ID: 14596699
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.
Shukuya T; Ko R; Mori K; Kato M; Yagishita S; Kanemaru R; Honma Y; Shibayama R; Koyama R; Shimada N; Takahashi K
Cancer Chemother Pharmacol; 2015 Oct; 76(4):771-6. PubMed ID: 26259641
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial.
Gautschi O; Rothschild SI; Li Q; Matter-Walstra K; Zippelius A; Betticher DC; Früh M; Stahel RA; Cathomas R; Rauch D; Pless M; Peters S; Froesch P; Zander T; Schneider M; Biaggi C; Mach N; Ochsenbein AF;
Clin Lung Cancer; 2017 May; 18(3):303-309. PubMed ID: 27993482
[TBL] [Abstract][Full Text] [Related]
15. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
16. EGFR Mutation Genotype Impact on the Efficacy of Pemetrexed in Patients with Nonsquamous Nonsmall Cell Lung Cancer.
Igawa S; Sato Y; Ishihara M; Kasajima M; Kusuhara S; Nakahara Y; Otani S; Fukui T; Katagiri M; Sasaki J; Masuda N
Asian Pac J Cancer Prev; 2016; 17(7):3249-53. PubMed ID: 27509958
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of pemetrexed-based doublet therapy compared to pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer: an updated meta-analysis.
Zhong A; Xiong X; Shi M; Xu H
Drug Des Devel Ther; 2015; 9():3685-93. PubMed ID: 26229433
[TBL] [Abstract][Full Text] [Related]
18. Pemetrexed disodium for the treatment of NSCLC: an update.
Hsu JY; Wakelee H
Drugs Today (Barc); 2008 Sep; 44(9):669-78. PubMed ID: 19137122
[TBL] [Abstract][Full Text] [Related]
19. Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancer.
Shen L; Niu X; Jian H; Xu Y; Yu Y; Lu S
Lung Cancer; 2017 Sep; 111():43-50. PubMed ID: 28838396
[TBL] [Abstract][Full Text] [Related]
20. [Impact of histology on efficacy of pemetrexed: pemetrexed in second-line setting and as maintenance therapy after first-line treatment in Chinese patients with advanced NSCLC].
Zhou C; Wu Y; Sun Y; Wang Y; Wang X; Zhang X
Zhonghua Zhong Liu Za Zhi; 2014 Jan; 36(1):29-33. PubMed ID: 24685083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
